The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Abstract
IL-6 contributes to host defense against infections and tissue injuries. However, exaggerated, excessive synthesis of IL-6 while fighting environmental stress leads to an acute severe systemic inflammatory response known as 'cytokine storm', since high levels of IL-6 can activate the coagulation pathway and vascular endothelial cells but inhibit myocardial function. Remarkable beneficial effects of IL-6 blockade therapy using a humanized anti-IL-6 receptor antibody, tocilizumab were recently observed in patients with cytokine release syndrome complicated by T-cell engaged therapy. In this review we propose the possibility that IL-6 blockade may constitute a novel therapeutic strategy for other types of cytokine storm, such as the systemic inflammatory response syndrome including sepsis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Self-citationSevere Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Conference, F. T. I. S. D., Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., et al. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1662-x · Cited by 2,871
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Cited by
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Diabetes is a risk factor for the progression and prognosis of COVID‐19
Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., Du, K., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3319 · Cited by 1,404
“5-81] vs 23 [10-49]), as well as D-dimer (1.”
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Liu, B., Li, M., Zhou, Z., Guan, X., & Xiang, Y. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102452 · Cited by 763
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Cytokine storm induced by SARS-CoV-2
Song, P., Li, W., Xie, J., Hou, Y., & You, C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.017 · Cited by 537
Cytokine storm intervention in the early stages of COVID-19 pneumonia
Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J., Liao, H., Zhi, L., Wei, H., Zhang, Z., Qiu, Y., et al. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.04.002 · Cited by 513
“IL6, which is an important target in CRS induced by adoptive cell therapy, can lead to vascular leakage, activation of complement and the coagulation cascade, leading to the characteristic symptoms of severe CRS, such as diffuse intravascular coagulation (DIC) [5,6].”
Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019
Zhu, Z., Cai, T., Fan, L., Lou, K., Hua, X., Huang, Z., & Gao, G. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.04.041 · Cited by 435
Silva Andrade, B., Siqueira, S., de Assis Soares, W. R., de Souza Rangel, F., Santos, N. O., dos Santos Freitas, A., Ribeiro da Silveira, P., Tiwari, S., Alzahrani, K. J., Góes-Neto, A., et al. (2021) · Viruses · doi:10.3390/v13040700 · Cited by 435
Interleukin (IL-6) Immunotherapy
Tanaka, T., Narazaki, M., & Kishimoto, T. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 407
Self-citationInterplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Self-citationChemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., Capela, C., Pedrosa, J., Castro, A. G., & Silvestre, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613422 · Cited by 355
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., De Santis, M., Acosta-Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 312
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 310
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections
Remy, K. E., Mazer, M., Striker, D. A., Ellebedy, A. H., Walton, A. H., Unsinger, J., Blood, T. M., Mudd, P. A., Yi, D. J., Mannion, D. A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140329 · Cited by 309
Girija, A. S. S., Shankar, E. M., & Larsson, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01206 · Cited by 308
Interleukin-6 in Rheumatoid Arthritis
Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., & Nucera, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155238 · Cited by 278
Zhao, M. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105982 · Cited by 274
Liu, Y., Zhang, C., Huang, F., Yang, Y., Wang, F., Yuan, J., Zhang, Z., Qin, Y., Li, X., Zhao, D., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa037 · Cited by 269
Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes
Mauvais-Jarvis, F., Klein, S. L., & Levin, E. R. (2020) · Endocrinology · doi:10.1210/endocr/bqaa127 · Cited by 266
Rabaan, A. A., Al-Ahmed, S. H., Muhammad, J., Khan, A., Sule, A. A., Tirupathi, R., Mutair, A. A., Alhumaid, S., Al-Omari, A., Dhawan, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9050436 · Cited by 255
Pilot trial of high-dose vitamin C in critically ill COVID-19 patients
Zhang, J., Rao, X., Li, Y., Zhu, Y., Liu, F., Guo, G., Luo, G., Meng, Z., De Backer, D., Xiang, H., et al. (2021) · Annals of Intensive Care · doi:10.1186/s13613-020-00792-3 · Cited by 253
The clinical importance of a cytokine network in the acute phase of sepsis
Matsumoto, H., Ogura, H., Shimizu, K., Ikeda, M., Hirose, T., Matsuura, H., Kang, S., Takahashi, K., Tanaka, T., & Shimazu, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32275-8 · Cited by 193
Self-citationZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.112 · Cited by 182
Hepatic natural killer T‐cell and CD8+ T‐cell signatures in mice with nonalcoholic steatohepatitis
Bhattacharjee, J., Kirby, M., Softic, S., Miles, L., Salazar‐Gonzalez, R., Shivakumar, P., & Kohli, R. (2017) · Hepatology Communications · doi:10.1002/hep4.1041 · Cited by 146
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Self-citationMechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
Sabaka, P., Koščálová, A., Straka, I., Hodosy, J., Lipták, R., Kmotorková, B., Kachlíková, M., & Kušnírová, A. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05945-8 · Cited by 130
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
Creeden, J. F., Imami, A. S., Eby, H. M., Gillman, C., Becker, K. N., Reigle, J., Andari, E., Pan, Z. K., O’Donovan, S. M., McCullumsmith, R. E., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111437 · Cited by 61
Ng, K. T.-P., Pang, L., Wang, J.-Q., She, W. H., Tsang, S. H.-Y., Lo, C. M., Man, K., & Cheung, T. T. (2024) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/j.hbpd.2023.10.006 · Cited by 5
Metadata
- Authors
- Tanaka, T., Narazaki, M., & Kishimoto, T.
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- 8
- Issue
- 8
- Pages
- 959-970
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W2471732223
- Cited by
- 708
- References
- 99
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.